Return to content in this issue

 

Safety of new MRNA Vaccines Against COVID-19 in Severe Allergic Patients

Rojas-Pérez-Ezquerra P1,2*, Crespo Quirós J1,2*, Tornero Molina P1,2, Baeza Ochoa de Ocáriz ML1,2,3, Zubeldia Ortuño JM1,2,3

1Allergy Service. Hospital General Universitario Gregorio Marañón. Madrid, Spain.
2Gregorio Marañón Health Research Institute (IiGSM). Madrid, Spain.
3Biomedical Research Network on Rare Diseases (CIBERER)-U761, Madrid, Spain.
*These authors contributed equally to this work.

J Investig Allergol Clin Immunol 2021; Vol. 31(2)
doi: 10.18176/jiaci.0683

Key words: Anaphylaxis, COVID-19 pandemic, Polyethilene glycol, PEG 2000, mRNA vaccines

Title Type Size
doi10.18176_jiaci.0683_material-suppl.pdf pdf 399.94 Kb